Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Core Insights - Ardelyx, Inc. is set to hold a conference call on August 4, 2025, to discuss its financial results and provide a business update for Q2 2025 [1] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]